Anika Therapeutics Q1 2025 10-Q Filed
Ticker: ANIK · Form: 10-Q · Filed: May 9, 2025 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financial-reporting, healthcare
TL;DR
Anika Therapeutics Q1 2025 10-Q is in. Financials and stock plans detailed.
AI Summary
Anika Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and business segments are presented, along with information on stock-based compensation plans.
Why It Matters
This filing provides investors with the latest financial results and operational details for Anika Therapeutics, crucial for understanding the company's current performance and future outlook.
Risk Assessment
Risk Level: medium — The filing contains standard financial reporting for a public company, but the specific financial performance and strategic details within the 10-Q could indicate varying levels of risk.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of fiscal year 2025)
- 20250331 — Period End Date (The 10-Q covers financial data up to this date.)
Key Players & Entities
- Anika Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 0000898437 (company) — Central Index Key for Anika Therapeutics, Inc.
- 32 WIGGINS AVENUE (address) — Business and Mail Address
- BEDFORD (location) — City of business and mail address
- MA (location) — State of business and mail address
- 01730 (zip_code) — Zip code of business and mail address
- (781) 457-9000 (phone_number) — Business phone number
FAQ
What were Anika Therapeutics' total revenues for the first quarter of 2025?
The filing does not explicitly state total revenues for Q1 2025 in the provided snippet, but it indicates the reporting period is January 1, 2025, to March 31, 2025.
What is the company's primary business address?
The company's business address is 32 WIGGINS AVENUE, BEDFORD, MA 01730.
When was the company formerly known as Anika Research Inc.?
The company changed its name from Anika Research Inc. on January 14, 1997.
What is the SIC code for Anika Therapeutics?
The Standard Industrial Classification code for Anika Therapeutics is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Does the filing mention any share repurchase plans?
Yes, the filing references an 'May2024ShareRepurchasePlanRule10b51Member' and 'May2024ShareRepurchasePlanMember' initiated around May 28, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Anika Therapeutics, Inc. (ANIK).